Rituximab: Emerging treatment strategies of immune-mediated glomerular disease

Expert Review of Clinical Immunology

Volumn 8, Issue 5, 2012, Pages 413-421

  Kattah, Andrea G ^a   Fervenza, Fernando C ^a  

^a MAYO CLINIC   (United States)

Author keywords

ANCA; lupus nephritis; membranoproliferative glomerulonephritis; membranous nephropathy; rituximab; vasculitis

Indexed keywords

ALKYLATING AGENT; ANTIHISTAMINIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHIMERIC ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DOUBLE STRANDED DNA ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PARACETAMOL; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; PLACEBO; RECEPTOR ANTIBODY; RITUXIMAB; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VELTUZUMAB;

ANCA ASSOCIATED VASCULITIS; ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; BRONCHOSPASM; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHURG STRAUSS SYNDROME; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FOCAL GLOMERULOSCLEROSIS; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GLOMERULOPATHY; GOVERNMENT REGULATION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFERTILITY; INFUSION RELATED REACTION; INNATE IMMUNITY; INSULIN RESISTANCE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MICROSCOPIC POLYANGIITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; MULTIPLE SCLEROSIS; NEOPLASM; NEPHROTIC SYNDROME; NONHODGKIN LYMPHOMA; OSTEOPOROSIS; PANCYTOPENIA; PNEUMOCYSTIS PNEUMONIA; PREMEDICATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; URTICARIA; VOMITING; WEGENER GRANULOMATOSIS; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CLINICAL TRIALS AS TOPIC; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; LUPUS NEPHRITIS; TREATMENT OUTCOME;

EID: 84865027447     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.26     Document Type: Review

References (81)

1. Finkielman JD, Lee AS, Hummel AM et al.; WGET Research Group. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am. J. Med. 120(7), 643.e9-14 (2007
2. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J. Am. Soc. Nephrol. 17(5), 1235-1242 (2006
3. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20(5), 517-527 (2004
4. Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361(1), 11-21 (2009
5. Fabrizi F, Lunghi G, Messa P, Martin P. Therapy of hepatitis C virus-associated glomerulonephritis: Current approaches. J. Nephrol. 21(6), 813-825 (2008
6. Lipsky PE. Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nat. Immunol. 2(9), 764-766 (2001
7. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy. Arthritis Rheum. 48(6), 1484-1492 (2003
8. Genovese MC, Kaine JL, Lowenstein MB et al.; ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A Phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 58(9), 2652-2661 (2008
9. Rigby W, Tony HP, Oelke K et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group Phase III trial. Arthritis Rheum. 64(2), 350-359 (2012
10. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr. Opin. Rheumatol. 23(3), 245-251 (2011
11. Kappos L, Li D, Calabresi PA et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A Phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805), 1779-1787 (2011
12. østergaard M, Baslund B, Rigby W et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebocontrolled, Phase I/II study. Arthritis Rheum. 62(8), 2227-2238 (2010
13. Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48(8), 2146-2154 (2003
14. Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol. 122(1), 62-74 (2007
15. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173(2), 180-187 (2006
16. Fervenza FC. Rituximab in ANCA-associated vasculitis: Fad or fact? Nephron. Clin. Pract. 118(2), c182-c188; discussion c188 (2011
17. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: Mechanism of antibodydependent cellular cytotoxicity and impact of human serum. J. Immunother. 29(4), 388-397 (2006
18. Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complementmediated cell lysis. Blood 95(12), 3900-3908 (2000
19. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20(4), 444-449 (2008
20. Stone JH, Merkel PA, Spiera R et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCAassociated vasculitis. N. Engl. J. Med. 363(3), 221-232 (2010
21. Fervenza FC, Cosio FG, Erickson SB et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 73(1), 117-125 (2008
22. Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol. Dial. Transplant. 26(9), 2865-2871 (2011
23. Fervenza FC, Abraham RS, Erickson SB et al.; Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin. J. Am. Soc. Nephrol. 5(12), 2188-2198 (2010
24. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6), 2188-2195 (1997
25. Clayton AR, Savage CO. Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis. Clin. Exp. Immunol. 132(1), 174-179 (2003
26. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 52(1), 262-268 (2005
27. Lovric S, Erdbruegger U, Kümpers P et al. Rituximab as rescue therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A single-centre experience with 15 patients. Nephrol. Dial. Transplant. 24(1), 179-185 (2009
28. Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60(7), 2156-2168 (2009
29. Jones RB, Tervaert JW, Hauser T et al. European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363(3), 211-220 (2010
30. Specks U, Stone JH; for the RAVE-ITN Research Group. Long-term efficacy and safety results of the RAVE trial. Clin. Exp. Immunol. 164, 65 (2011
31. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 361(9357), 587-594 (2003
32. Keogh KA, Specks U. Churg-Strauss syndrome. Semin. Respir. Crit. Care Med. 27(2), 148-157 (2006
33. Donvik KK, Omdal R. Churg-Strauss syndrome successfully treated with rituximab. Rheumatol. Int. 31(1), 89-91 (2011
34. Pepper RJ, Fabre MA, Pavesio C et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 47(7), 1104-1105 (2008
35. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann. Rheum. Dis. 65(8), 1116-1117 (2006
36. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann. Rheum. Dis. 65(4), 557-559 (2006
37. Cattran DC. Membranous nephropathy: Quo vadis? Kidney Int. 61(1), 349-350 (2002
38. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 360(9337), 923-924 (2002
39. Cravedi P, Noris M, Remuzzi G. Report of the first World Transplant Congress. Clin. J. Am. Soc. Nephrol. 2(2), 393-400 (2007
40. Ruggenenti P, Chiurchiu C, Brusegan V et al. Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J. Am. Soc. Nephrol. 14(7), 1851-1857 (2003
41. McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998
42. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54(8), 2377-2386 (2006
43. Ruggenenti P, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin. J. Am. Soc. Nephrol. 1(4), 738-748 (2006
44. Herishanu Y. Rituximab-induced serum sickness. Am. J. Hematol. 70(4), 329 (2002
45. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised Phase III trial. ATTRACT Study Group. Lancet 354, 1932-1939 (1999
46. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50(8), 2580-2589 (2004
47. Davis TA, Grillo-López AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J. Clin. Oncol. 18(17), 3135-3143 (2000
48. Zaja F, Iacona I, Masolini P et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 87(2), 189-195 (2002
49. Beck LH Jr, Fervenza FC, Beck DM et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22(8), 1543-1550 (2011
50. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: A systematic review. Clin. J. Am. Soc. Nephrol. 4(4), 734-744 (2009
51. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: Pathogenetic heterogeneity and proposal for a new classification. Semin. Nephrol. 31(4), 341-348 (2011
52. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 64(3), 835-842 (2012
53. De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 64(3), 843-853 (2012
54. Quartuccio L, Soardo G, Romano G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: Efficacy and safety in the absence of steroids. Rheumatology (Oxford) 45(7), 842-846 (2006
55. Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC. Rituximab therapy for type I membranoproliferative glomerulonephritis. Clin. Nephrol. 77(4), 290-295 (2012
56. Cameron JS. Lupus nephritis. J. Am. Soc. Nephrol. 10(2), 413-424 (1999
57. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353(21), 2219-2228 (2005
58. Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 314(10), 614-619 (1986
59. Boumpas DT, Austin HA 3rd, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340(8822), 741-745 (1992
60. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum. 52(2), 501-513 (2005
61. Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56(4), 1263-1272 (2007
62. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46(10), 2673-2677 (2002
63. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 54(9), 2970-2982 (2006
64. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62(1), 222-233 (2010
65. Rovin BH, Furie R, Latinis K et al.; for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab (LUNAR) Study. Arthitis Rheum. 64(4), 1215-1226 (2012
66. Francois H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: First case report and pathophysiological considerations. Am. J. Kidney Dis. 49(1), 158-161 (2007
67. Hofstra JM, Deegens JK, Wetzels JF. Rituximab: Effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol. Dial. Transplant. 22(7), 2100-2102 (2007
68. Fujinaga S, Hirano D, Nishizaki N et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr. Nephrol. 25(3), 539-544 (2010
69. Kisner T, Burst V, Teschner S, Benzing T, Kurschat CE. Rituximab treatment for adults with refractory nephrotic syndrome: A single-center experience and review of the literature. Nephron. Clin. Pract. 120(2), c79-c85 (2012
70. Sawara Y, Itabashi M, Kojima C et al. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin. Nephrol. 72(1), 69-72 (2009
71. Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf )-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol. Dial. Transplant. 23(1), 377-380 (2008
72. Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin. Nephrol. 76(2), 151-158 (2011
73. Fernandez-Fresnedo G, Segarra A, González E et al.; Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 4(8), 1317-1323 (2009
74. Prytula A, Iijima K, Kamei K et al. Rituximab in refractory nephrotic syndrome. Pediatr. Nephrol. 25(3), 461-468 (2010
75. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin. J. Am. Soc. Nephrol. 5(12), 2363-2372 (2010
76. Gottenberg JE, Guillevin L, Lambotte O et al.; Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64(6), 913-920 (2005
77. Larsen JL, Jacobsen S. Rapid infusion with rituximab: Short term safety in systemic autoimmune diseases. Rheumatol. Int. doi:10.1007/s00296-011-2208-0 (2011) (Epub ahead of print
78. Choy DS, Weiss A, Lin PT. Progressive multifocal leukoencephalopathy following treatment for Wegener's granulomatosis. JAMA 268(5), 600-601 (1992
79. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease. Arthritis Rheum. 56(7), 2116-2128 (2007
80. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J. Infect. Chemother. 11(4), 189-191 (2005
81. Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br. J. Dermatol. 155(5), 1053-1056 (2006